The cardioprotective effect of rivaroxaban combined with low dose aspirin greatly outweighs the bleeding risk, especially in high-risk patients, a new analysis of the landmark COMPASS study shows. In 2017 the rivaroxaban trial in people with stable cardiovascular disease was stopped early because of “overwhelming efficacy” in reducing the risk of MI, stroke and cardiovascular ...
Rivaroxaban cardioprotective benefits outweigh bleeding risks
By Michael Woodhead
27 May 2020